Nuvilex's TD2 is being done for all abdominal cancers...at first I thought it was just for pancreatic cancer until the verbiage changed in the PR's...they are not working toward approval for symptoms just for pancreatic cancer...when they go for approval it will be for all abdominal cancers...
VERBIAGE CHANGES...
Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid...
" announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as "malignant ascites," in the abdomen that is characteristic of the growth of many abdominal tumors."
Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development...
"In an effort to keep our shareholders informed on the very important preclinical studies to determine if Nuvilex's unique treatment of cancer can slow the accumulation of fluid in the abdomen, known as "malignant ascites," that is characteristic of the growth of many abdominal tumors, including pancreatic cancer"
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
"Nuvilex, Inc. (otcqb:NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers"
Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients...
"These are two commonly occurring symptoms associated with advanced pancreatic cancer as well as other abdominal cancers"
" Nuvilex and TD2 may very well be on the path to proving that the combination of Cell-in-a-Box/ifosfamide can benefit those suffering from pancreatic cancer and all other abdominal cancers where the growth of tumors is causing intense pain and where ascites is prevalent. "
"In another major announcement two weeks ago, Nuvilex stated that it and Translational Drug Development (TD2) officially began the first of 4 different pre-clinical studies that will determine what effect the company's pancreatic cancer treatment will have on symptoms associated with abdominal cancers."...
"These are just a few of the abdominal cancers, and as should be obvious by the 5.4 million new cases they represent annually, Nuvilex is potentially developing a treatment that could compete in what is a huge and virtually untapped symptoms market."
bull
